Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

In Advanced Prostate Cancer, Degarelix Offers Advantages Over LHRH Agonists

October 31st 2013

Men with advanced prostate cancer who took the GnRH antagonist degarelix experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events than did those patients who took LHRH agonists.

Pre-Chemo Trial of Enzalutamide Halted After Meeting Endpoints

October 22nd 2013

The phase III PREVAIL trial of enzalutamide in chemotherapy-naÃ¯ve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival

Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active Surveillance

October 16th 2013

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

Abiraterone Stalls Pain, Quality of Life Decline in mCRPC

October 11th 2013

Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.

First Approved Alpha Emitter Bolsters Arsenal Against Prostate Cancer

October 10th 2013

With the recent approval of a first-in-class radioactive isotope as a treatment for prostate cancer, urologists have a new weapon in their rapidly growing arsenal of therapies designed to fight this disease.

Biomarkers Predict Prognosis for Patients With mCRPC

October 3rd 2013

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer

Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent Alone

October 1st 2013

Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.

AUA Issues Recommendations for PSA Screening in Prostate Cancer Detection

September 27th 2013

At a time of controversy regarding the value of PSA screening in the early detection of prostate cancer, the AUA has issued a new clinical guideline on the subject and launched an educational campaign designed to share the information with urologists and their patients.

Dr. Shore Comments on the Approval of Radium-223

September 19th 2013

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

New Data May Dispel Safety Concerns With 5-ARI Use in Prostate Cancer Prevention

September 19th 2013

The Prostate Cancer Prevention Trial, conducted from January 1997 to February 2003, demonstrated that the 5Î±-reductase inhibitor (5-ARI) finasteride reduced the risk of developing prostate cancer in men being regularly screened for the disease

Herbal Supplement Could Outperform Observation in Some Patients With Recurrent Prostate Cancer

September 18th 2013

A cocktail of herbs and vitamins lowered PSA in more than a third of patients with biochemically recurrent prostate cancer, and thus may be a good alternative to observation in this population.

Ipilimumab Fails to Prolong Survival in mCRPC

September 12th 2013

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

Updated Phase III Data Show Radium-223 Significantly Improves Survival, Extends Time to First SRE

September 10th 2013

An updated analysis of the results of a phase III clinical trial showed that radium-223 dichloride (Xofigo) significantly improved overall survival and delayed time to the first skeletal-related event in patients with metastatic prostate cancer.

Dr. Gulley Discusses Vaccine Responses

September 10th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

Dr. Crawford Compares Degarelix and LHRH Agonists

September 9th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Dr. Vogelzang Discusses the Prostate Health Cocktail

September 5th 2013

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Novel Drug Studies Yield Biomarker Candidates for Prostate Cancer Bone Turnover

September 4th 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

Dr. Sartor on Progress for the Treatment of Prostate Cancer

September 3rd 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Dr. Shore on Radium-223 Patient Considerations

August 26th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Advances in Prostate Cancer Treatment Highlighted at ASCO

August 19th 2013

At the 2013 ASCO Annual Meeting, researchers presented the latest developments with enzalutamide, radium-223, and abiraterone acetate as treatments for patients with advanced prostate cancer.